Advances in Precision Medicine and New Therapies for Psoriatic Arthritis

Recent research presented at major rheumatology meetings highlights advances in precision medicine approaches for psoriatic arthritis, including a biopsy-driven therapeutic strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combination therapies, and biomarker panels. These developments address the disease's biological heterogeneity and the current lack of validated predictive biomarkers for treatment selection.

A real-world proof-of-concept study presented at the 2026 EULAR Congress compared a biopsy-driven therapeutic strategy with standard clinical management in 35 patients with psoriatic arthritis. Synovial samples were classified into three pathotypes: myeloid, lympho-myeloid, and pauci-immune. Fifteen patients with a myeloid CD117-positive pathotype received biologics directed against IL-17, IL-23, or TNF, while a matched control group of 20 patients was treated based on standard clinical judgement without biopsy guidance. The primary clinical endpoint of low disease activity or remission was achieved in 68% of patients receiving biopsy-driven treatment, compared with 45% in the control group. In those with the myeloid pathotype, mean reduction in DAPSA at 6 months was markedly greater with IL-17 and IL-23 inhibitors compared with TNF inhibitors. The findings suggest a biological basis for differential response to therapy and highlight the central role of the IL-17/23 axis in this subgroup.

Another study presented at EULAR examined the role of diet in 92 patients with active psoriatic arthritis and a mean body mass index of 33. Participants were randomized to a Mediterranean diet, a low-calorie diet targeting weight reduction, or a standard-of-care control arm. All groups experienced modest, statistically significant weight loss by Week 12 with no significant difference between approaches. The primary endpoint of change in DAPSA showed significant reductions in the low-calorie and control groups, and by Week 24 all groups showed improvement with no significant differences between groups. Importantly, the magnitude of weight loss was significantly associated with improvement in clinical outcomes, independent of the dietary intervention.

New biologic agents and combinations are also expanding treatment options. Interleukin-17 and IL-23 inhibitors may be better than TNF inhibitors for skin manifestations, though nothing has actually beaten TNF inhibitors in terms of efficacy for joint disease. The BE-BOLD study compared the IL-17 inhibitor bimekizumab with the IL-23 inhibitor risankizumab, showing bimekizumab did better in joint response. The ICONIC LEAD study assessed the oral IL-23 targeted agent icotrokinra, which showed significant skin clearance in psoriasis, with potential benefits for compliance, cost, and access.

Combination therapy is returning as a potential approach in psoriatic arthritis, particularly following negative data from early biologic therapy days. The VEGA study combined IL-23 and TNF inhibition with some success and no new safety signals. Combination therapy with ixekizumab alongside the GLP-1 receptor agonist tirzepatide has also shown effectiveness. However, combination therapies are not expected to reach the market quickly.

Treatment sequencing remains an area of active debate, especially after biologic failure. Patients who stopped a TNF inhibitor due to inefficacy rather than intolerance may be more likely to benefit from targeting a different inflammatory pathway. Unanswered questions include why some patients persist on therapy longer than others and why women appear to have shorter drug survival than men.

Despite decades of investigation, no single biomarker has emerged to direct therapy in psoriatic arthritis. Researchers believe the future may lie not in one test, but in composite panels capable of capturing multiple inflammatory signals and disease domains, similar to multi-biomarker approaches used in other rheumatic diseases.